Sarepta Therapeutics released detailed safety outcomes for its Duchenne muscular dystrophy gene therapy Elevidys, affirming a positive benefit-risk profile in ambulatory patients with zero acute liver failure deaths reported in this subgroup. However, non-ambulatory patients experienced safety challenges, including fatalities from liver injury, prompting intensified safety initiatives and black box warnings. Concurrently, Sarepta sold Arrowhead Pharmaceuticals stock holdings to bolster cash reserves and meet milestone obligations, reflecting ongoing financial strategy amidst challenging regulatory scrutiny.